Preparing an Integrated Summary of Safety: A Writer’s Perspective

被引:0
|
作者
Sharie Myers
Beth Baron
Lyn Radke-Mitchell
Maira Rieger
Mary Alice Miller
机构
[1] Division of Warner-Lambert Company,Clinical Communications Department, Parke
[2] Medical Writing,Davis Pharmaceutical Research
[3] Statprobe,undefined
来源
Drug information journal : DIJ / Drug Information Association | 1998年 / 32卷 / 1期
关键词
Integrated Summary of Safety; Writer’s perspective;
D O I
暂无
中图分类号
学科分类号
摘要
The Integrated Summary of Safety (ISS) submitted with a New Drug Application is used by sponsors and regulators to evalutate a new drug’s safety profile. Preparing an ISS is a labor and intellectually intensive process requiring input from many areas of expertise within the pharmaceutical company including medical writing, regulatory affairs, clinical research, biometrics, data management, and programming. This article describes the approach to document production used at Parke-Davis Pharmaceutical Research Division of Warner Lambert Company and some guidelines for preparing an ISS from a writer’s perspective.
引用
收藏
页码:53 / 63
页数:10
相关论文
共 50 条
  • [21] Preparing for the professoriate: A graduate student's perspective.
    Miller, KE
    Skogerboe, KJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U430 - U430
  • [22] Preparing for the threat of a pandemic: a Canadian student's perspective
    Ng, Derek C. K.
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2009, 3 (07): : 575 - 578
  • [23] Preparing Graduates for Careers in Publishing: A Publisher's Perspective
    Baker, Robert F.
    EDUCATIONAL PSYCHOLOGIST, 1985, 20 (02) : 102 - 106
  • [24] Preparing for a Joint Commission survey: A pharmacist's perspective
    Chamallas, SN
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (03) : 275 - 277
  • [25] A Writer's Perspective: An Interview with FASP Author Abigail Padgett
    Hartwell, Laura M.
    RECHERCHE ET PRATIQUES PEDAGOGIQUES EN LANGUES DE SPECIALITE-CAHIERS DE L APLIUT, 2011, 30 (02): : 138 - 148
  • [26] Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102)
    Falcone, A.
    Ohtsu, A.
    Van Cutsem, E.
    Mayer, R.
    Buscaglia, M.
    Bendell, J. C.
    Kopetz, S.
    Wahba, M.
    Bebeau, P.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Safety: a manufacturer's perspective
    Wierenga, Elisabeth J.
    PERFUSION-UK, 1997, 12 (04): : 229 - 231
  • [28] A Brief Summary of Carbon Nanotubes Science and Technology: A Health and Safety Perspective
    Wick, Peter
    Clift, Martin J. D.
    Roesslein, Matthias
    Rothen-Rutishauser, Barbara
    CHEMSUSCHEM, 2011, 4 (07) : 905 - 911
  • [29] Safety and tolerability of cariprazine in long-term treatment of schizophrenia: integrated summary of safety data
    Nasrallah, H. A.
    Cutler, A. J.
    Wang, Y.
    Lu, K.
    Nagy, K.
    Laszlovszky, I.
    Durgam, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S536 - S536
  • [30] Safety and tolerability of cariprazine in long-term treatment of schizophrenia: Integrated summary of safety data
    Durgam, S.
    Nasrallah, H. A.
    Nasrallah, Henry A.
    Cutler, A.
    Wang, Y.
    Lu, K.
    Nagy, K.
    Laszlovszky, I.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2014, 17 : 68 - 68